No Data
No Data
Are Strong Financial Prospects The Force That Is Driving The Momentum In CSPC Innovation Pharmaceutical Co., Ltd.'s SZSE:300765) Stock?
cspc innovation pharmaceutical (300765.SZ): elected company director, general manager Yao Bing as chairman of the board
CSPC Innovation Pharmaceutical (300765.SZ) issued an announcement, the board of directors of the company received the company's chairman Pan Weidong and director Yang Dong...
cspc innovation pharmaceutical (300765.SZ): Repurchase completed, cumulatively spent 0.321 billion yuan to repurchase 0.85% of shares.
As of September 23, cspc innovation pharmaceutical (300765.SZ) announced that as of the disclosure date of this announcement, the company's current share repurchase program has been fully implemented. As of September 20, 2024, the company repurchased 12,000,225 shares of the company through a stock repurchase dedicated securities account in a centralized auction trading method, accounting for 0.85% of the company's current total share capital. The highest fill price was 34.99 yuan/share, the lowest fill price was 18.68 yuan/share, and the total amount paid was 320,987,996.60 yuan (excluding transaction costs). The repurchase period has expired, and the total amount of repurchased shares has exceeded.
CSPC Innovation Pharmaceutical (SZSE:300765) Sheds 3.6% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Huafu Securities: Significant differentiation in pharmaceutical interim reports, bullish on Pharma and innovative drugs.
Fundamentally, last week saw a high concentration of pharmaceutical mid-year reports, with some differentiation but overall industry pressure and bearish expectations materializing. Considering the upward year-on-year growth rate in the industry in Q3, along with the upcoming catalytic factors such as the implementation of innovative drug industry chain support policies and the start of medical insurance negotiations, the overall trend of the industry is upward.
CSPC Innovation Pharmaceutical's (SZSE:300765) Sluggish Earnings Might Be Just The Beginning Of Its Problems
No Data
No Data